Neura.net: Perspectives on CNS Disease Management


	Advanced Search

Text Size

Tuesday, September 07, 2010

Home

Home > Nurse Network > MS Scan > Issue 24 (2009)

Issue 24 (2009)

Download MS Scan Issue 24 (2009)

Featured in this issue of MS Scan are summaries of recent studies regarding quality of life (QoL) in MS, MS-related fatigue, and clinical trials in primary-progressive MS (PPMS) and clinically isolated syndrome (CIS). One study examines gender differences in health-related QoL in MS. A round-up of 6 clinical trials tracks the latest findings on MS fatigue. A review of recent PPMS publications reveals the frustrating, yet hopeful search for an efficacious treatment for progressive MS. Finally, early disease-modifying therapy (DMT) in CIS is examined in detail, with a review of recent clinical trials.

Gender and Quality of Life
Although women have about twice the risk of developing MS as men, they also have slightly better outcomes in terms of life-expectancy and time to progression of disability. This article considers a recent cross-sectional study that has shined a spotlight on the gender gap between MS-related disability and QoL in patients with MS.

Clinical Trials for PPMS Yield Frustration and Hope
PPMS has been called both an enigma and a major therapeutic challenge, as effective treatment options remain an elusive goal for researchers. This article reviews the latest PPMS literature, including the results of 2 double-blind clinical trials that assessed treatment efficacy. The future of PPMS trials is also addressed.

Research Roundup on MS Fatigue
Recent publications on fatigue, the most common symptom reported by people with MS, are summarized. One study suggests that MS-related fatigue involves both physiologic and psychological components, some directly related to MS and others secondary to the disease. Another explores biological pathways and treatments. Also discussed are findings supporting the importance of exercise in the management of MS-related fatigue.

Early Treatment for CIS: An Unfolding Success Story
Most people who develop MS initially experience a single episode of inflammatory demyelination, or clinically isolated syndrome (CIS). In clinical trials, DMT initiated at this first episode of demyelination has been shown to delay progression to clinically definite MS (CDMS). Findings from clinical trials of 4 DMTs (the 3 interferon β formulations and glatiramer acetate) are reviewed.

Neura.net is administered, managed, and populated by Expert Medical Education, a company dedicated to the education of healthcare professionals. The individual educational materials available here are supported by educational grants from Teva Neuroscience. This site is intended for U.S. audiences only. This Web site is for use by healthcare professionals only. It is not meant to serve as a substitute for a consultation with your physician. If you are a patient and would like to see Neura.net's educational material for patients, click here. Some discussions of drugs and devices contained on this Web site may include mention of uses that have not been evaluated by the United States Food and Drug Administration for safety and efficacy. Please consult complete prescribing information for any of the drugs and devices discussed before using them.
© 2010 Neura.net. All rights reserved.